Key Insights

Highlights

Success Rate

89% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

3.9%

2 terminated out of 51 trials

Success Rate

88.9%

+2.4% vs benchmark

Late-Stage Pipeline

6%

3 trials in Phase 3/4

Results Transparency

6%

1 of 16 completed with results

Key Signals

1 with results89% success

Data Visualizations

Phase Distribution

42Total
Not Applicable (25)
Early P 1 (3)
P 1 (5)
P 2 (6)
P 3 (3)

Trial Status

Recruiting22
Completed16
Active Not Recruiting7
Withdrawn3
Terminated2
Suspended1

Trial Success Rate

88.9%

Benchmark: 86.5%

Based on 16 completed trials

Clinical Trials (51)

Showing 20 of 20 trials
NCT05969860Phase 2Recruiting

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

NCT05035667Active Not Recruiting

Patient Considerations of Social Media Account Management After Death

NCT06198010Not ApplicableRecruitingPrimary

A Collaborative Intervention for Improving Cancer Pain Management in Cancer Survivors

NCT06305884Not ApplicableCompletedPrimary

Transcutaneous Sensors for the Detection of Cancer-Related Lymphedema, Project Limb Rescue Study

NCT07221409Not ApplicableRecruiting

Virtual Reality Intervention to Improve Psychological Symptom Burden for Cancer Patients Undergoing Treatment

NCT03471260Phase 1Recruiting

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

NCT06192875RecruitingPrimary

A Novel Molecular Approach to Blood DNA Screening for Cancer: Specificity Assessment (The NOMAD Study)

NCT06059391Phase 2Recruiting

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

NCT06151730Recruiting

Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study

NCT05564468Not ApplicableCompletedPrimary

Design and Testing of a Web-Based Tool for the Improvement of End-of-Life Planning in Patients With Advanced Cancer

NCT04977024Phase 2Active Not Recruiting

SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

NCT05411523Recruiting

Assessing Effect of Spinal Cord Stimulation on Pain and Quality of Life With Chemotherapy-Induced Peripheral Neuropathy

NCT05584449Not ApplicableRecruitingPrimary

Group Curriculum for Improving Survivorship Outcomes in Adolescent and Young Adult Cancer Survivors

NCT06169267Phase 3Active Not RecruitingPrimary

Passive Music Intervention for the Reduction of Anxiety in Patients Undergoing Bone Marrow Aspiration and/or Biopsy

NCT04494945Not ApplicableRecruiting

Identifying and Caring for Individuals With Inherited Cancer Syndrome

NCT05477784Not ApplicableTerminated

Cancer Parenting Program for the Enhancement of the Quality of Life of Patients With Advanced Cancer and Their Children

NCT04022239Phase 1RecruitingPrimary

Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

NCT05772130Not ApplicableRecruitingPrimary

Provider-Mediated Communication of Genetic Testing Results to At-Risk Relatives of Cancer Patients to Improve Genetic Counseling and Testing Rates, Family HOPE Study

NCT04572815Phase 2Active Not Recruiting

Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant

NCT05868486Early Phase 1Active Not RecruitingPrimary

Analysis of Whole Body Magnetic Resonance Imaging and Liquid Biopsy for Early Detection of Cancer in Patients With a Strong Family History of Cancer

Scroll to load more

Research Network

Activity Timeline